Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano
INTRODUCTION
Despite remarkable recent advances in its treatment, multiple myeloma remains incurable. 1 Allografting is still regarded as the only potential cure on account of its well-documented graft-vs.myeloma effect observed in a subset of patients. [2] [3] [4] [5] However, its use remains controversial especially in newly diagnosed patients.
In the late '90s, the introduction of reduced intensity / non-myeloablative conditionings greatly renewed the interest in allografting in particular for diseases such as myeloma where the transplant-related mortality (TRM) with conventional transplant regimens had been unacceptably high. [5] [6] [7] Combining the cytoreductive effect of a high-dose melphalan-based autograft with the graft-vs.-myeloma effects of a non-myeloablative allograft reduced TRM even in elderly, medically unfit myeloma patients. 8, 9 Our recent comparison between autografting and non-myeloablative allografting showed that the latter resulted in longer overall and event-free survivals in newly diagnosed patients younger than 65 years. 10 Preliminary reports from other groups have confirmed our findings. 11, 12 Here, we report on an extended experience consisting of 100 newly diagnosed myeloma patients enrolled in a prospective clinical trial (ClinicalTrial.gov, NCT-00702247) and treated with non-myeloablative allografts as part of their first-line treatment at fifteen Italian Bone Marrow Transplantation Units of the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). donation. Exclusion criteria included: prior treatment for myeloma; abnormal cardiac function and chronic respiratory disease defined as systolic ejection fraction < 35% and carbon monoxide diffusing capacity < 40% of predicted or need of continuous supplemental oxygen, respectively; serum bilirubins > twice normal, and ALAT and/or ASAT > four times normal; poorly controlled hypertension; pregnancy, seropositivity for HIV. Patients with active non-hematologic malignancies, except non-melanoma skin cancers, or who were less than 5 years from the achievement of complete remission with a >20% risk of disease recurrence were also excluded.
METHODS

Patients and donors
Sibling donors < 75 years of age were serologically matched for HLA-A , B and C antigens, and by high resolution typing for HLA-DRB1 and DQB1 alleles. Donors gave consent to granulocyte-colony stimulating factor (G-CSF) administration and to leukapheresis for PBSC collections. Pregnant women, identical twins, HIV-positive individuals and potential donors with known allergy to G-CSF were excluded from donation.
Induction therapy, PBSC mobilization and autografting Initial treatment plan included
induction chemotherapy, mainly consisting of 2-3 courses of vincristine-adriamycin-dexamethasone (VAD)-based regimens, followed by PBSC mobilisation and harvest (target of at least 2 x 10 6 CD34 cells/kg) after 1 or 2 cycles of cyclophosphamide, 3-4 g/m 2 , with or without paclitaxel, 250 mg/m 2 , and G-CSF, 10 g/kg given i.v. or subcutaneously. After at least one month from PBSC collection, autografting consisted of melphalan, 200 mg/m 2 , on day -2, and cryopreserved PBSC infusion on day 0. Patients received G-CSF, 5 g/kg, from days 1 or 3 until neutrophil counts >1000/ l were achieved.
Donor mobilisation HLA-identical sibling donors, mean age 54 (range 32-69) years, were mobilised with G-CSF, 16 g/kg/day (day -4 to 0), with aphereses on days -1 and 0. PBSC harvested on day -1 were stored overnight at 4ºC and freshly infused with the day 0 collection. The entire collections were infused and a minimum target of 5 x 10 6 CD34-positive cells/kg of recipient body weight was recommended. No upper limit was defined.
Non-myeloablative allografting Upon recovery from autografting, defined as resolved mucositis, no evidence of cytomegalovirus (CMV) reactivation or disease, and no need for intravenous medications, planned range of 2-4 months, patients were conditioned for allografting with a single dose of non-myeloablative 200 cGy total body irradiation (TBI) on day 0. Postgrafting immunosuppression consisted of mycophenolate mofetil, 15 mg/kg orally BID from the evening of day 0 until day 27, and cyclosporine, 6.25 mg/kg orally BID from day -3 or 1.5 mg/kg iv BID from day -1 through day 80 and then tapered. 9, 10 No maintenance/consolidation therapy was allowed by protocol after non-myeloablative allografting.
Analyses of chimerism Chimerism analyses of peripheral blood T cells, granulocytes and
unfractionated marrow were carried out at days 28, 56, 180, 360 after allografting and every six months thereafter or as clinically indicated with fluorescence in situ hybridization (FISH) in sexmismatched pairs or polymerase chain reaction (PCR)-based analyses of polymorphic microsatellite regions in sex-matched pairs as previously described. 9, 10 Chromosomal abnormalities 13q deletion (del13) was analysed by interphase FISH techniques on freshly purified bone marrow plasma cells as previously described. 13 Supportive care and GVHD grading Following allografting, all patients received standard prophylaxis against bacterial and fungal infections; herpes simplex and varicella-zoster virus reactivation; and Pneumocystis carinii. CMV reactivation was monitored through levels of CMV antigenemia and/or serum CMV DNA levels and treated with ganciclovir or foscarnet as clinically indicated. Standard criteria were used for diagnosis and grading of acute and chronic GVHD. 14, 15 Salvage therapy Standard chemotherapy and/or thalidomide-or bortezomib-containing regimens, as per Institutional guidelines of the participating Centers, with/without donor lymphocytes infusions (DLI) were allowed to treat progression or relapse post-transplant. DLI were administered in the absence of GVHD clinical manifestation and after a rapid taper and discontinuation of the immunosuppression.
Disease response
Response was evaluated prior to each treatment, monthly for the first six months following allografting and at least every three months thereafter or as clinically indicated.
Response criteria were defined according to the International Uniform Response Criteria for multiple myeloma. 16 Complete remission (CR) required absence of serum monoclonal immunoglobulins and/or Bence-Jones proteinuria by electrophoresis and immunofixation, less than 5% plasma cell infiltration in bone marrow aspirates, absence of soft tissue lesions and no increase in size or number of osteolytic lesions. Very good partial remission (VGPR) was defined as detection of serum monoclonal immunoglobulins and/or Bence-Jones proteinuria by immunofixation but not by electrophoresis or at least 90% reduction in Bence-Jones proteinuria with excretion lower than 100 mg /24-hour, and no increase in size or number of osteolytic lesions.
Partial remission (PR) was defined as >75% reduction in the levels of serum monoclonal immunoglobulin, at least 90% reduction in 24-hour urinary light chain excretion, and no increase in size or number of lytic bone lesions. Patients with less than a PR after induction chemotherapy or autografting were considered refractory, whereas the disease was considered stable if no response, meeting the criteria of CR, VGPR or PR, was observed after allografting. Response criteria had to be met on at least two consecutive occasions at least six weeks apart. Progressive disease (PD) was considered an increase in serum monoclonal proteins or urine light chains of a least 25% in patients with refractory or stable disease, whereas relapse was considered as the reappearance of bone marrow infiltration, serum monoclonal immunoglobulins or urine light chains or new bone lesions in patients in previous CR, or a 25% increase in any disease marker for patients in prior PR.
Statistical analysis
Primary endpoints of the study were overall (OS) and event-free survivals (EFS) from diagnosis according to the intention-to-treat principle and in patients who completed the program. Secondary endpoints included transplant-related toxicity and TRM and incidence of acute and chronic GVHD. OS and EFS were calculated according to the Kaplan-Meier technique from the date of diagnosis until death from any cause and from the date of diagnosis until the date of first relapse or progression or of death from any cause, respectively. 17 Deaths not related to myeloma or to non-hematological malignancies were classified as deaths from transplant-related toxicity.
Moreover, an estimation of the probability that a patient was alive in the original remission or in a subsequent remission after salvage treatment was carried out by the "Current Progression Free Survival" (CPFS) method as described by Klein et al. 18 Estimates of the incidence of acute and chronic GVHD, TRM and disease-related mortality were calculated with the cumulative incidence method described by Gooley et al, in which risks of death in CR and of relapse were considered as competing risks. 19 The individual effect of patient characteristics on time from allografting to five different events (relapse/progression, death, CR after transplant, chronic extensive GVHD and acute grade II-IV GVHD) were evaluated using Cox's proportional-hazards regression models with the Wei-Lin-Weissfeld estimators. [20] [21] [22] [23] Proportional hazard assumptions were checked with the Grambsh and Therneau test. 24 Table 1 . Overall, 100 patients with at least one HLA-identical sibling were enrolled at fifteen Italian Bone Marrow Transplantation Units. Ninetysix/100 (96%) completed the protocol whereas 4 did not because of consent withdrawal (no=2); infectious complications after the autograft (no=1); ineligible donor at pre-transplant work-up (no=1). Fifty-two, also described in an earlier report, have been included in this series after updating their follow-up. 10 (Figure 1-B) . By multivariable analysis, an increasing number of CD34+ cells infused, but not CD3+ T cells, was associated with a significant risk of developing acute GVHD, but not chronic GVHD (HR 1.12, CI 95% 1.04-1.21, p<0.01 and HR 1.03, CI 95% 0.94-1.13, p=0.55) ( Table 2 ). Furthermore, the development of chronic GVHD was not significantly associated with either the subsequent achievement of CR or disease relapse/progression (HR 0.80, CI 95% 0.43-1.47, p=0.47 and HR 0.85, CI 95% 0.51-1.42, p=0.54) ( Table 2) . the previously reported cohort of 52 patients 10 and the newly described 44 were observed (HR 0.58, CI 95% 0.28-1.2, p=0.14 and HR 0.93, CI 95% 0.55-1.56, p=0.78, respectively). Furthermore, the probability of a patient being alive in first remission or in a subsequent remission due to salvage therapy is illustrated in Figure 3 .
RESULTS
Patients Patient characteristics are shown in
Engraftment and Response
Multivariable analyses for OS and EFS are reported in Table 3 . Irrespective of myeloma isotype, ISS, comorbidity index ≥ 3, disease in remission was significantly associated with longer OS and EFS (HR 0.20, CI 95% 0.06-0.67, p=0.01 and HR 0.33, CI 95% 0.17-0.65, p<0.01). Age, as a continuous variable, was also significantly associated with both OS and EFS (HR 1.06, CI 95% (Figure 4-A, 4-B) .
DISCUSSION
Progress in myeloma treatment has been impressive in the past ten years with the introduction of high-dose melphalan followed by autologous transplantation and, recently, through the identification of new agents with molecular targets such as thalidomide, lenalidomide and bortezomib. [27] [28] [29] [30] [31] [32] OS has been significantly prolonged especially in good risk patients, whereas eradication of the disease seems unlikely. Conversely, in the light of a well-documented graft-vs.myeloma effect, allografting may be curative in a subset of patients. 5, 33, 34 However, its role has never been thoroughly investigated. First, the high transplant-related toxicity associated with myeloablative conditionings has severely limited its application; second, the retrospective nature of several studies with strong patient selection bias and the lack of large prospective controlled trials have not allowed definitive conclusions. 7 One of the strengths of our study is the rigid enrolment at diagnosis of untreated myeloma patients who underwent the same VAD-based induction treatment before the autologous cytoreductive transplant. This strategy meant that they were all treated uniformly and any statistical bias was greatly reduced. By contrast, prospective studies which include allografting as part of the up-front treatment regardless of the induction therapy inevitably result in bias that may highly affect the clinical outcomes.
In the present study, median OS was not reached after a follow-up of 5 years. Before the era of "new drugs", after a median follow-up of 75 months, Attal et al. reported median OS of 48 and 58 months after one and two autologous transplants respectively. 28 Barlogie et al. 35 reported that 17% of the patients enrolled in the Total Therapy 1 trial were alive at 15 years, 7% event free, after a median follow-up of 12 years. 29 More recently, with a follow-up of 7 years, the thalidomide arm of Total Therapy 2 has appeared to further improve clinical outcomes. 35 Overall, 53% (51/96) of patients reached CR, 73% (37/51) of whom are in continuous CR, including molecular remissions (Ladetto M., personal communication), prelude to a cure, with a follow-up extending to 8 years. Thus, the depth of response was crucial for prolonged response in our study (Table 3 ). 36 Given the high rate of CR obtained without the use of so-called "new drugs", it is imperative to thoroughly explore their role in the setting of allografting. Graft-vs.-myeloma effects and "new drugs" with molecular targets, in fact, are by no means mutually exclusive.
Bortezomib and thalidomide have already been shown to re-induce remissions in patients who relapsed following allografting. Anti-myeloma activity has also been shown at relapse in the series of patients reported in this study (Figure 3 ). We are currently investigating the role of lenalidomide in reducing the tumor burden before and enhancing graft-vs-myeloma effect after transplant. Maintenance therapy may lead to a significant increase in response rates and prolonged response duration. Furthermore, this strategy may also overcome the higher risk of relapse in patients with poor prognostic factors. 40 Overall, non-relapse mortality was 11%. GVHD and its complications accounted for most TRM. Its incidence, however, may be further reduced as progress is made in the understanding of its pathogenesis. 41 Chronic GVHD has often been associated with longer response duration and better OS. 42 In our study, however, its development did not correlate with either subsequent achievement of CR or response duration ( Table 2 ). In a subset of patients, therefore, a graft-vs.myeloma effect may be distinct from detrimental chronic GVHD or associated with subclinical graft-vs.-host reactions. The potential biological effects of the number of donor CD34-pos cells infused have been debated in several studies. 43, 44 Interestingly, we noted that an increasing number of CD34-pos cells infused, but not CD3-pos T cells, was significantly correlated with a higher risk of developing acute GVHD ( Table 2 ). An upper limit of CD34-pos cells infused was not included in our trial. Evaluation of their number in a larger series of patients may help to set a range that allows consistent donor engraftment while reducing the risk of acute GVHD.
It is widely assumed that chromosomal abnormalities are important prognostic factors for both OS and EFS. 45 Garban et al. reported OS and EFS of 35 and 31.7 months respectively, after a median follow-up of 2 years, in high risk newly diagnosed myeloma patients, with either elevated β-2-microglobulin levels or presence of del (13) , who received reduced-intensity allografts. 46 Perhaps because the conditioning with high-dose anti-thymocyte globulin may have attenuated graft-vs.-myeloma effects, a survival benefit with allografting as compared to melphalan-based autografting was not observed. 47 In another comparison, the advantage of having an HLA identical sibling, therefore the chance of undergoing an allograft, as compared to not having an HLAidentical sibling was not offset by the presence of del (13) . 10 This finding, however, did not imply that in patients given allografts, del(13) might not have had a prognostic role. In the present series, del(13) appeared to significantly affect EFS (4.3 vs. 2.2 years, p=0.01), but not OS (not reached vs. 4.3 years, p=0.18). The data reported in all these studies should, however, be evaluated with larger and more comprehensive analyses that include a complete spectrum of the chromosomal abnormalities associated with myeloma rather than a single abnormality. Recent reports clearly showed that del(13) alone did not affect OS after transplant unless it was associated with other abnormalities such as del (17) or t (4;14) . 47 Whether an allograft should be offered as part of first-line treatment plan or as salvage therapy for refractory or relapsed patients is a matter of debate. 48 Patients who did not achieve at least near-CR after a first autograft were randomized to receive either a second autograft or an allograft after a reduced-intensity-conditioning in the light of the presence/absence of an HLA-identical sibling donor. There was a significantly higher incidence of CR and a longer progression-free survival in patients treated with an allograft. However, there was also a higher TRM and no statistical difference in EFS and OS. The Authors concluded that, although the progression-free survival plateau was encouraging, the procedure should be investigated in prospective clinical trials. Though different in design, the findings of the PETHEMA study are not conflicting with our trial. In particular, we clearly observed that disease response at the time of the allograft was significantly associated with post-transplant EFS and OS (Tables 2 and   3 ).
In summary, our findings suggested that allografting was effective in the treatment of newly 
